The Medical Letter
@themedicalletter.bsky.social
A nonprofit organization that has provided independent reviews of drugs and therapeutics since 1959. Funded solely by subscriptions and donations. Because the source matters.
Answer: b
A meta-analysis of five randomized trials in children with influenza found that starting oseltamivir within 48 hrs after illness onset reduced illness duration by ~18 hrs (by about 30 hrs when trials that enrolled children with asthma were excluded) and decreased the risk of otitis media.
A meta-analysis of five randomized trials in children with influenza found that starting oseltamivir within 48 hrs after illness onset reduced illness duration by ~18 hrs (by about 30 hrs when trials that enrolled children with asthma were excluded) and decreased the risk of otitis media.
November 4, 2025 at 8:50 PM
Answer: b
A meta-analysis of five randomized trials in children with influenza found that starting oseltamivir within 48 hrs after illness onset reduced illness duration by ~18 hrs (by about 30 hrs when trials that enrolled children with asthma were excluded) and decreased the risk of otitis media.
A meta-analysis of five randomized trials in children with influenza found that starting oseltamivir within 48 hrs after illness onset reduced illness duration by ~18 hrs (by about 30 hrs when trials that enrolled children with asthma were excluded) and decreased the risk of otitis media.
6. Answer: d
The labels of JAK inhibitors such as delgocitinib cream warn about increased risks of severe adverse effects, including major adverse cardiovascular events, thrombosis, lymphoma and other malignancies, serious infections, and death.
The labels of JAK inhibitors such as delgocitinib cream warn about increased risks of severe adverse effects, including major adverse cardiovascular events, thrombosis, lymphoma and other malignancies, serious infections, and death.
October 21, 2025 at 7:04 PM
6. Answer: d
The labels of JAK inhibitors such as delgocitinib cream warn about increased risks of severe adverse effects, including major adverse cardiovascular events, thrombosis, lymphoma and other malignancies, serious infections, and death.
The labels of JAK inhibitors such as delgocitinib cream warn about increased risks of severe adverse effects, including major adverse cardiovascular events, thrombosis, lymphoma and other malignancies, serious infections, and death.
Answer: b
Meloxicam has COX-2 selectivity in vitro, which decreases at higher dosages; it has been associated with lower rates of some GI-related adverse effects than nonselective NSAIDs, and it is less likely to inhibit platelet function.
Meloxicam has COX-2 selectivity in vitro, which decreases at higher dosages; it has been associated with lower rates of some GI-related adverse effects than nonselective NSAIDs, and it is less likely to inhibit platelet function.
October 14, 2025 at 3:29 PM
Answer: b
Meloxicam has COX-2 selectivity in vitro, which decreases at higher dosages; it has been associated with lower rates of some GI-related adverse effects than nonselective NSAIDs, and it is less likely to inhibit platelet function.
Meloxicam has COX-2 selectivity in vitro, which decreases at higher dosages; it has been associated with lower rates of some GI-related adverse effects than nonselective NSAIDs, and it is less likely to inhibit platelet function.
Answer: d
Vaccination against influenza should continue to be offered as long as influenza viruses are circulating in the community. Vaccination in July or August may result in suboptimal immunity before the end of the influenza season, especially in adults ≥65 years old.
Vaccination against influenza should continue to be offered as long as influenza viruses are circulating in the community. Vaccination in July or August may result in suboptimal immunity before the end of the influenza season, especially in adults ≥65 years old.
October 7, 2025 at 9:08 PM
Answer: d
Vaccination against influenza should continue to be offered as long as influenza viruses are circulating in the community. Vaccination in July or August may result in suboptimal immunity before the end of the influenza season, especially in adults ≥65 years old.
Vaccination against influenza should continue to be offered as long as influenza viruses are circulating in the community. Vaccination in July or August may result in suboptimal immunity before the end of the influenza season, especially in adults ≥65 years old.